Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CUTERA INCCUTR · Entity 82936 | Director | October 24, 2024 | November 05, 2024 |
| Intersect ENT, Inc.XENT · Entity 127294 | Chief Financial Officer | May 07, 2019 | May 08, 2019 |
| Minerva Neurosciences, Inc.NERV · Entity 6245 | Director | September 27, 2023 | September 29, 2023 |
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| Omada Health, Inc.OMDA · Entity 2364 | Director | October 05, 2026 | October 07, 2026 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director | June 04, 2026 | June 09, 2026 |
| Talis Biomedical CorpTLIS · Entity 87664 | Director | March 16, 2021 | March 18, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CUTERA INC
Report date October 24, 2024 · Filed November 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2031-10-23 | Direct | 40,000 |
Reported balance
After 2024-10-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-10-24 · Grant · Acquired 14,673 · Balance 40,000 F1: All shares vest on the earlier of 12 months from grant date, or on the day of the 2025 annual stockholder meeting, subject to the Reporting Person continuing to be a service provider of the Company. F2: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: All shares vest on the earlier of 12 months from grant date, or on the day of the 2025 annual stockholder meeting, subject to the Reporting Person continuing to be a service provider of the Company.
F2: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company.
Intersect ENT, Inc.
Report date May 07, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 43,836 |
Reported balance
After 2019-05-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-05-07 · Grant · Acquired 11,952 · Balance 43,836 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest on December 31, 2019. F2: Includes 35,952 Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest on December 31, 2019.
F2: Includes 35,952 Restricted Stock Units.
Minerva Neurosciences, Inc.
Report date September 27, 2023 · Filed September 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2033-09-26 | Direct | 12,500 |
Reported balance
After 2023-09-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-27 · Grant · Acquired 12,500 · Balance 12,500 F1: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year. F2: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year.
F2: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date.
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 25,471 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 25,471 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Omada Health, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,869 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 1,214 · Balance 27,869 F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.
SI-BONE, Inc.
Report date June 04, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 43,772 |
Reported balance
After 2026-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 10,957 · Balance 43,772 F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date.
F2: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Talis Biomedical Corp
Report date March 16, 2021 · Filed March 18, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.60 · Expires 2031-03-15 | Direct | 35,112 |
Reported balance
After 2021-03-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-16 · Grant · Acquired 35,112 · Balance 35,112 F1: 1/36th of the shares subject to the option shall vest monthly over the three years from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/36th of the shares subject to the option shall vest monthly over the three years from the grant date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HilleVax, Inc.
Report date September 17, 2025 · Filed September 17, 2025
Section 16 reporting ended · disclosed 2025-09-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-09-17 transaction · row 1
1 source rowRow 1 · 2025-09-17 · Other · Disposed 59,224 · Balance 0 F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:14 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,214 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000428 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,869 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| July 05, 2026 Filed Jul 7, 2026 23:26 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,299 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000324 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,519 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| July 05, 2026 Filed Jul 20, 2026 23:16 UTC Amendment | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000340 · form4a.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,655 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. F2 · shares: This Form 4/A is being filed solely to correct the number of RSUs reported as granted on July 5, 2026, and the total number of shares beneficially owned by the Reporting Person. Due to an administrative error, the original Form 4 filing understated the number of RSUs that were granted pursuant to the Program. This amendment corrects the error to reflect the actual number of RSUs granted and the shares beneficially owned by the Reporting Person following the grant. F2 · balance_after: This Form 4/A is being filed solely to correct the number of RSUs reported as granted on July 5, 2026, and the total number of shares beneficially owned by the Reporting Person. Due to an administrative error, the original Form 4 filing understated the number of RSUs that were granted pursuant to the Program. This amendment corrects the error to reflect the actual number of RSUs granted and the shares beneficially owned by the Reporting Person following the grant. Read SEC document |
| June 16, 2026 Filed Jun 18, 2026 20:25 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 10,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000254 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,220 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, subject to continued service through such vesting date. Read SEC document |
| June 04, 2026 Filed Jun 9, 2026 18:50 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon stock | 10,957 | $0.00 | $0.00 |
DisclosureSEC source: 0001216628-26-000003 · primary_doc.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,772 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 10,957 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,999 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001216628-26-000002 · primarydocument.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 03, 2026 Filed Jun 5, 2026 20:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,610 | $0.00 | $0.00 |
DisclosureSEC source: 0001216628-26-000002 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,471 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:53 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,945 | $15.77 | $46,444.71 |
DisclosureSEC source: 0001216628-26-000001 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,861 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| April 05, 2026 Filed Apr 7, 2026 20:07 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000143 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,338 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 22:36 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-26-000004 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,794 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| October 05, 2025 Filed Oct 7, 2025 20:41 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-044510 · wk-form4_1759869683.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,238 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| October 05, 2025 Filed Dec 18, 2025 23:57 UTC Amendment | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 1,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000425 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,193 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. F2 · shares: The original Form 4 filed by the Reporting Person inadvertently overstated the amount of securities acquired and beneficially owned by 45 shares. This Form 4 amendment is being filed to correct the aforementioned errors. F2 · balance_after: The original Form 4 filed by the Reporting Person inadvertently overstated the amount of securities acquired and beneficially owned by 45 shares. This Form 4 amendment is being filed to correct the aforementioned errors. Read SEC document |
| September 17, 2025 Filed Sep 17, 2025 20:30 UTC | HilleVax, Inc. HLVX · Entity 75097 | OtherCommon Stock | 59,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-206253 · ownership.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with that certain Agreement and Plan of Merger, dated as of August 4, 2025 (the "Merger Agreement"), by and among the Issuer, XOMA Royalty Corporation ("Parent") and XRA 4 Corp., a wholly owned subsidiary of Parent ("Merger Sub" and together with Parent, the "Purchasers"), the Purchasers completed a tender offer to acquire all of the issued and outstanding shares of Common Stock of the Issuer in exchange for (a) $1.95 in cash per share (the "Cash Amount"), plus (b) one contingent value right ("CVR") representing the right to receive certain contingent cash payments equal to the "CVR Proceeds" as further described in that certain CVR Agreement entered into between the Purchasers and a representative to the CVR holders. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of September 17, 2025 (the "Effective Time"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding restricted stock unit ("RSU") immediately vested in full and was canceled in exchange for the right to receive (a) an amount in cash, without interest, equal to the product obtained by multiplying (x) the Cash Amount by (y) the number of shares underlying such RSU at the Effective Time and (b) one CVR for each share underlying such RSU. Read SEC document |
| July 05, 2025 Filed Jul 8, 2025 21:18 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 376 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000281 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,112 F1 · shares: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 20:13 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantCommon Stock | 17,199 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089951 · ownership.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,224 F1 · shares: The Restricted Stock Units ("RSUs") were granted on June 23, 2025 pursuant to the Registrant's Non-Employee Director Compensation Program. 100% of the total number of RSUs granted shall vest on the first to occur of (i) the first anniversary of the date of grant or (ii) a Change in Control (as defined in the Registrant's 2022 Incentive Award Plan), in each case, subject to the non-employee director continuing in service on the Registrant's board of directors through such vesting date. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 23:45 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004610 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,815 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,675 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:13 UTC | Omada Health, Inc. OMDA · Entity 2364 | GrantCommon Stock | 9,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001610717-25-000178 · form4.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,736 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs will fully vest on the first anniversary of June 5, 2025. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 16,697 | $0.00 Strike: $16.72 | $0.00 |
DisclosureSEC source: 0001562180-25-004559 · primarydocument.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004559 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,806 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 999 | $17.26 | $17,246.54 |
DisclosureSEC source: 0001562180-25-004431 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,591 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| October 24, 2024 Filed Nov 5, 2024 16:17 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 14,673 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001628280-24-045300 · wk-form4_1730841420.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: COMMON STOCK · 14,673 shares Expires 2031-10-23 F1 · derivative.exercise_date: All shares vest on the earlier of 12 months from grant date, or on the day of the 2025 annual stockholder meeting, subject to the Reporting Person continuing to be a service provider of the Company. F2 · derivative.expiration_date: The expiration date is subject to earlier expiration upon the termination of the Reporting Person's service with the Company. Read SEC document |
| July 12, 2024 Filed Jul 16, 2024 19:06 UTC | CUTERA INC CUTR · Entity 82936 | GrantStock Option (Right to Buy) · Derivative | 25,327 | $0.00 Strike: $1.47 | $0.00 |
DisclosureSEC source: 0001628280-24-031994 · wk-form4_1721171156.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,327 Underlying: COMMON STOCK · 25,327 shares Expires 2031-07-12 F1 · derivative.exercise_date: The stock option vests in equal installments on each of the one-year, two-year, and three-year anniversaries of the grant date. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 21:49 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005327 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,140 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 13,657 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 06, 2024 Filed Apr 30, 2025 11:00 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $13.75 | $0.00 |
DisclosureSEC source: 0000950170-25-060558 · ownership.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 6,229 | $0.00 Strike: $23.13 | $0.00 |
DisclosureSEC source: 0001562180-24-004749 · primarydocument.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F2 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| June 05, 2024 Filed Jun 6, 2024 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 4,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-004749 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,590 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 12:58 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001209191-23-050826 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-09-26 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 12,500 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following September 27, 2023 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 20, 2023 Filed Jun 20, 2023 22:02 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,081 | $28.00 | $58,268.00 |
DisclosureSEC source: 0001562180-23-005383 · primarydocument.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,349 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · balance_after: Includes 4,866 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 22:02 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 2,081 | $28.74 | $59,807.94 |
DisclosureSEC source: 0001562180-23-005383 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,430 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 20:27 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 4,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005110 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,511 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 4,866 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 12,554 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005012 · primarydocument.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 Underlying: Ordinary Shares · 12,554 shares Expires 2033-06-06 F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 22:36 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantStock Option · Derivative | 22,500 | $0.00 Strike: $17.94 | $0.00 |
DisclosureSEC source: 0000899243-23-015279 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2033-06-06 F1 · derivative.exercise_date: The option was granted pursuant to the Registrant's non-employee director compensation program. The option shall vest and/or become exercisable on the first to occur of (i) the first anniversary of the grant date or (ii) the next occurring annual meeting of our stockholders, in each case, subject to the non-employee director continuing in service on our board of directors through such vesting dates. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 20:35 UTC | HilleVax, Inc. HLVX · Entity 75097 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $12.38 | $0.00 |
DisclosureSEC source: 0000899243-22-029530 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-18 F1 · derivative.exercise_date: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 20:02 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005231 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,645 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,324 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 13, 2022 Filed Jun 14, 2022 18:50 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,924 | $13.81 | $26,561.97 |
DisclosureSEC source: 0001562180-22-005093 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,321 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $13.8045 to $13.84, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. Read SEC document |
| June 10, 2022 Filed Jun 16, 2022 20:22 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 407 | $69.61 | $28,331.27 |
DisclosureSEC source: 0001645113-22-000057 · wf-form4_165541090953677.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,537 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Hilleman. Read SEC document |
| June 10, 2022 Filed Jun 28, 2022 23:36 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $3.32 | $0.00 |
DisclosureSEC source: 0001209191-22-039689 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2032-06-09 F1 · security: This option is granted to non-employee directors in accordance with the Issuer's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 2,500 shares of common stock per year. F2 · derivative.exercise_price: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F3 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 10, 2022 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. F2 · derivative.underlying_shares: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. F2 · balance_after: On June 17, 2022, the Issuer completed a 1-for-8 reverse stock split of the Issuer's common stock ("Reverse Stock Split"). This amount has been adjusted to give effect to the Reverse Stock Split. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:08 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 8,700 | $0.00 Strike: $77.25 | $0.00 |
DisclosureSEC source: 0001645113-22-000050 · wf-form4_165489168529039.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Ordinary Shares · 8,700 shares Expires 2032-06-08 F1 · derivative.exercise_date: Options to buy 8,700 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document |
| June 25, 2021 Filed Jun 28, 2021 21:12 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 4,400 | $33.71 | $148,324.00 |
DisclosureSEC source: 0001562180-21-004532 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,245 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · balance_after: Includes 3,848 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 21:47 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-21-040680 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2021 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:41 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 3,848 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004254 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,645 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 3,848 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 1,499 | $0.00 Strike: $211.89 | $0.00 |
DisclosureSEC source: 0001645113-21-000076 · wf-form4_162344285531541.xml · derivative · entry 3 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 Underlying: Ordinary Shares · 1,499 shares Expires 2031-06-09 F3 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Disposition to issuerOrdinary Shares | 1,270 | $210.01 | $266,712.70 |
DisclosureSEC source: 0001645113-21-000076 · wf-form4_162344285531541.xml · nonDerivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,944 F2 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Hilleman. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:21 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 814 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-21-000076 · wf-form4_162344285531541.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,214 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:01 UTC | Talis Biomedical Corp TLIS · Entity 87664 | GrantStock Option (right to buy) · Derivative | 35,112 | $0.00 Strike: $17.60 | $0.00 |
DisclosureSEC source: 0001209191-21-021831 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,112 Underlying: Common Stock · 35,112 shares Expires 2031-03-15 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over the three years from the grant date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:38 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleRestricted Stock Units | 2,500 | $166.40 | $416,000.00 |
DisclosureSEC source: 0001628280-20-017711 · wf-form4_160868029605808.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,400 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Ms. Hilleman. Read SEC document |
| June 16, 2020 Filed Jun 18, 2020 22:24 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 8,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004588 · primarydocument.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting 100% upon the earlier of (i) the next annual general meeting of the stockholders of the Company or (ii) the date one year from the Vesting Commencement Date, subject to the Reporting Person's continuous service as a member of the Company's Board of Directors until such date. F2 · balance_after: Includes 8,797 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 20:59 UTC | Minerva Neurosciences, Inc. NERV · Entity 6245 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-20-036336 · doc4.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-06-10 F1 · security: This option is granted to non-employee directors in accordance with the Company's compensation program for non-employee directors, which provides that each non-employee director is eligible to receive an annual option grant to purchase 20,000 shares of common stock per year. F2 · derivative.exercise_date: The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 11, 2020 and an additional 1/4 every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000090 · wf-form4_159199992057717.xml · derivative · entry 2 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:12 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000090 · wf-form4_159199992057717.xml · nonDerivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,900 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.